Since the first edition of the World Orphan Drug Congress USA back in 2011, this forum has catered to the orphan drug industry’s most pressing challenges and opportunities to bring rare disease therapies to patients faster.
WODC USA has evolved from a one track conference focused on regulatory pathways, policy and incentives for 150 attendees in the US, to a global gathering of 800+ leaders in orphan drugs from 38 countries, and over 135 presentations covering all aspects of orphan drug development and rare disease research.
In 2017, our best edition yet, brought into light contentious and new discussions on Real World Evidence, Orphan Biosimilars, Expanded Access and Compassionate Use Programs, Gene Therapy, Personalized Medicine, Pricing and Reimbursement and more.
For 2018, we’re moving to a stellar venue – the Gaylord National Resort & Convention Center – right outside the D.C. area where over 1,000 attendees from over 50 countries will be gathered. With 12 new seminars and workshops on the pre-conference day, and a full 6-streams program including orphan drugs tracks on Regulatory, Clinical & Access Innovation; Commercialization; Global Market Access; Genetics & Diagnostics; as well as Rare Disease Advocacy World and Pitch & Partner, this is set to be the largest and most comprehensive orphan drugs conference in the world.
If your organization is entering the rare disease space or willing to take advantage of the arising opportunities to develop and market orphan drugs and deal with the emerging challenges in this sector, then you should participate at the World Orphan Drug Congress USA 2018!






Contact Andre Singer at andre.singer@terrapinn.com
or  +1 646 619 1797